TCL1A Antikörper (Alexa Fluor 647)

Produktnummer ABIN2658007

Produktdetails anti-TCL1A Antikörper (Alexa Fluor 647)

Target: TCL1A (T-Cell Leukemia/lymphoma 1A (TCL1A))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TCL1A Antikörper ist konjugiert mit Alexa Fluor 647

Applikation: Flow Cytometry (FACS)

Aufreinigung: The antibody was purified by affinity chromatography, and conjugated with Alexa Fluor® 647 under optimal conditions.

Klon: 1-21

Isotyp: IgG2b kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C

Details zu TCL1A

Target: TCL1A (T-Cell Leukemia/lymphoma 1A (TCL1A))

Andere Bezeichnung: TCL1 (TCL1A Produkte)

Synonyme: TCL1A antikoerper, Tcl1a antikoerper, TCL1 antikoerper, Tcl1 antikoerper, T-cell leukemia/lymphoma 1A antikoerper, T cell lymphoma breakpoint 1 antikoerper, TCL1A antikoerper, Tcl1 antikoerper, Tcl1a antikoerper

Hintergrund: TCL1, also known as T-cell leukemia/lymphoma protein 1A, protein p14 TCL1 and oncogene TCL-1, is a 14kD beta-barrel protein that was originally identified on the basis of its association with T-cell prolymphocytic leukemia (T-PLL). Activated by the T-cell receptor enhancer through inv(14)(q11,q32.1) or t(14,14)(q11,q32.1), TCL1 is normally expressed in immature cortical thymocytes, activated peripheral T-cells, pro-B cells, and naive mantle zone B cells of peripheral lymphoid tissues, but not in post-germinal center (GC) memory B cells and plasma cells. Akt and TCL1 interact via Akt's pleckstrin homology domain to form hetero-oligomers at the leaflet of the inner plasma membrane stimulating the protein kinase C-mitogen activated protein kinase-extracellular signal-related kinase (PKC-MAPK-ERK) signal transduction pathway. TCL1 also inhibits activation-induced cell death in T-cells by blocking PKCθ. In addition to T-PLL dysregulation is implicated in such B-cell neoplasias as lymphoblastic lymphoma, chronic lymphocytic leukemia (CLL) and Burkitt lymphoma.

Pathways: Stem Cell Maintenance